在局部晚期胃癌中使用FLOT与DOS新辅助化疗:倾向性评分分析
Lu-Yang Zhang1,2, Sen Zhang1,2, Xuan Zhao1,2
1Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.
International journal of clinical oncology
|October 7, 2025
概括
这项研究比较了新辅助剂甲,莱可沃林,氧化,多塞塔克塞尔 (FLOT) 和多塞塔克塞尔,氧化,S-1 (DOS) 对于局部发达的胃癌. DOS显示出有利的可行性,安全性和有效性,住院时间较短,这表明对患者和医疗保健的潜在益处.
科学领域:
- 在瘤学瘤学.
- 胃肠道瘤学 胃肠道瘤学
- 新辅助化学疗法 新辅助化学疗法
背景情况:
- 局部晚期胃癌 (LAGC) 需要有效的新辅助治疗.
- 甲,莱可沃林,氧化,多塞塔克塞尔 (FLOT) 和多塞塔克塞尔,氧化,S-1 (DOS) 用于LAGC.
- 没有直接比较FLOT和DOS的安全性和有效性.
研究的目的:
- 为了在LAGC患者中比较新辅助药FLOT与DOS疗法的安全性和有效性.
- 评估治疗反应,不良事件,手术结果和长期存活率.
- 为了确定LAGC最佳的新辅助化疗方案.
主要方法:
- 在2017-2021年期间接受治疗的LAGC患者的回顾性分析.
- 在FLOT组 (4周期) 的72名患者和在DOS组 (3周期) 的72名患者的倾向匹配比较.
- 评估RECIST反应,3/4级不良事件,手术/病理结果,R0切除率,总生存率 (OS) 和无进展生存率 (PFS).
主要成果:
- 对FLOT的RECIST响应率为41.7%,对DOS的响应率为47.2%.
- 在FLOT中,R0切除率为63.9%,在DOS中为72.2%.
- 在手术时间,血液损失,住院时间,瘤回归,术后发病率或3/4级毒性方面没有发现显著差异. 5年的OS率分别为42.7% (FLOT) 和50.4% (DOS),PFS率分别为33.7%和41.4%.
结论:
- 与LAGC中的FLOT相比,新辅助剂DOS显示出有利的可行性,安全性和有效性.
- 虽然在统计学上并不显著,但在响应率,R0切除和生存结果方面,趋势有利于DOS.
- 较短的DOS住院可能会改善患者的舒适度,并减少医疗负担.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.5K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
616
相关概念视频
01:21Cancer Survival Analysis
624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624
01:20Comparing the Survival Analysis of Two or More Groups
525
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
525